• Roberto Jiménez-Lima, Eder Arango-Bravo, Tatiana Galicia-Carmona, Leonardo S Lino-Silva, Guadalupe E Trejo-Durán, Cristina Alvarado-Silva, Omar H Castañeda-Renderos, Elva G Vanoye-Carlo, Celia Flores-de la Torre, Alfonso Dueñas-González, and Lucely Cetina-Pérez.
• Faculty of Medicine, Doctorate Program in Medical, Dental and Health Sciences, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.
• Rev Invest Clin. 2020 Jan 1; 72 (4): 231-238.

AbstractCervical cancer (CC) is one of the most common gynecological tumors and an important health problem, especially in developing countries. The vast majority of patients in early stages are cured of the disease with surgical treatment and with concomitant chemoradiotherapy in locally advanced stages. However, in patients with recurrent, persistent, or metastatic cervical CC, the effectiveness of treatment is limited, except for the combination of chemotherapy based on platinum doublets plus bevacizumab, the treatment that has achieved the best results to date. Programmed cell death-1/PD ligand-1 (PD-1/PD-L1) inhibitors could be a novel and cutting-edge therapeutic option to improve clinical outcomes in this group of patients. Thus far, there are a few Phase I/II clinical trials that have assessed the usefulness of pembrolizumab and nivolumab in this group of patients; these include the KEYNOTE 028, KEYNOTE 158, and CHECKMATE 358 trials, in which clinical benefit has been proven with PD-1/PD-L1 inhibitors in recurrent, persistent, or metastatic CC, as second-line treatment. There are also some ongoing trials that could provide further evidence on the PD-1/PD-L1 pathway as a therapeutic target in CC. In this review, we will focus on the usefulness of these PD-1/PDL1 inhibitors in CC, as well as on trials that are still in the recruitment phase, to confirm their effectiveness in this clinical setting.Copyright: © 2020 Permanyer.

14 keywords...

hide…